Antonello Mai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2000827/publications.pdf

Version: 2024-02-01

351 papers 15,744 citations

64 h-index 101 g-index

375 all docs

375 docs citations

times ranked

375

22616 citing authors

#	Article	IF	CITATIONS
1	The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. Cell, 2016, 167, 1145-1149.	28.9	404
2	$TNF/p38\hat{l}\pm/Polycomb$ Signaling to Pax7 Locus in Satellite Cells Links Inflammation to the Epigenetic Control of Muscle Regeneration. Cell Stem Cell, 2010, 7, 455-469.	11.1	346
3	BLUEPRINT to decode the epigenetic signature written in blood. Nature Biotechnology, 2012, 30, 224-226.	17.5	323
4	Histone deacetylation in epigenetics: An attractive target for anticancer therapy. Medicinal Research Reviews, 2005, 25, 261-309.	10.5	306
5	Sirtuin functions and modulation: from chemistry to the clinic. Clinical Epigenetics, 2016, 8, 61.	4.1	291
6	Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2. Journal of the American Chemical Society, 2010, 132, 6827-6833.	13.7	261
7	Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene, 2009, 28, 781-791.	5.9	244
8	HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19183-19187.	7.1	234
9	SIRT5 regulation of ammonia-induced autophagy and mitophagy. Autophagy, 2015, 11, 253-270.	9.1	223
10	The emerging role of epigenetics in human autoimmune disorders. Clinical Epigenetics, 2019, 11, 34.	4.1	200
11	Inhibition of Class I Histone Deacetylases Unveils a Mitochondrial Signature and Enhances Oxidative Metabolism in Skeletal Muscle and Adipose Tissue. Diabetes, 2013, 62, 732-742.	0.6	196
12	Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides. Journal of Medicinal Chemistry, 2005, 48, 3344-3353.	6.4	193
13	Oxidative Stress and Epigenetic Regulation in Ageing and Age-Related Diseases. International Journal of Molecular Sciences, 2013, 14, 17643-17663.	4.1	183
14	Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead. International Journal of Biochemistry and Cell Biology, 2009, 41, 199-213.	2.8	177
15	Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes and Cancer, 2011, 2, 663-679.	1.9	177
16	Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nature Communications, 2018, 9, 53.	12.8	175
17	Design, Synthesis, and Biological Evaluation of Sirtinol Analogues as Class III Histone/Protein Deacetylase (Sirtuin) Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 7789-7795.	6.4	159
18	HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer. Cancer Research, 2011, 71, 4412-4422.	0.9	159

#	Article	IF	CITATIONS
19	Study of 1,4-Dihydropyridine Structural Scaffold: Discovery of Novel Sirtuin Activators and Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 5496-5504.	6.4	147
20	Small-Molecule Inhibitors of Histone Acetyltransferase Activity:Â Identification and Biological Properties. Journal of Medicinal Chemistry, 2006, 49, 6897-6907.	6.4	134
21	Epigenetic Multiple Ligands: Mixed Histone/Protein Methyltransferase, Acetyltransferase, and Class III Deacetylase (Sirtuin) Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 2279-2290.	6.4	133
22	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes. EMBO Reports, 2009, 10, 776-782.	4. 5	125
23	Structural Basis of Sirtuin 6 Activation by Synthetic Small Molecules. Angewandte Chemie - International Edition, 2017, 56, 1007-1011.	13.8	125
24	Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis. Cancer Research, 2006, 66, 6785-6792.	0.9	124
25	Specific Control of Pancreatic Endocrine \hat{l}^2 - and \hat{l} -Cell Mass by Class IIa Histone Deacetylases HDAC4, HDAC5, and HDAC9. Diabetes, 2011, 60, 2861-2871.	0.6	119
26	Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clinical Epigenetics, 2017, 9, 59.	4.1	118
27	Nitric Oxide Modulates Chromatin Folding in Human Endothelial Cells via Protein Phosphatase 2A Activation and Class II Histone Deacetylases Nuclear Shuttling. Circulation Research, 2008, 102, 51-58.	4.5	114
28	3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 1. Design, Synthesis, Biological Evaluation, and Binding Mode Studies Performed through Three Different Docking Procedures. Journal of Medicinal Chemistry, 2003, 46, 512-524.	6.4	113
29	Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells. Journal of Medicinal Chemistry, 2014, 57, 701-713.	6.4	111
30	5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones:Â Novel Potent and Selective Dihydro-alkoxy-benzyl-oxopyrimidine Derivatives. Journal of Medicinal Chemistry, 1999, 42, 619-627.	6.4	109
31	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines:Â Novel Non-Nucleoside Reverse Transcriptase Inhibitors of theS-DABO Series. Journal of Medicinal Chemistry, 1997, 40, 1447-1454.	6.4	106
32	Pan-Histone Demethylase Inhibitors Simultaneously Targeting Jumonji C and Lysine-Specific Demethylases Display High Anticancer Activities. Journal of Medicinal Chemistry, 2014, 57, 42-55.	6.4	105
33	1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 6259-6265.	6.4	102
34	"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology, 2009, 6, 52.	2.0	100
35	Small Molecule Inhibitors of Histone Arginine Methyltransferases:  Homology Modeling, Molecular Docking, Binding Mode Analysis, and Biological Evaluations. Journal of Medicinal Chemistry, 2007, 50, 1241-1253.	6.4	98
36	Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2788-2792.	2.2	96

#	Article	IF	CITATIONS
37	Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells. Molecular Cancer Research, 2008, 6, 1908-1919.	3.4	95
38	Preparation and anti-HIV-1 activity of Thio Analogues of Dichydroalkoxybenzyloxopyrimidines. Journal of Medicinal Chemistry, 1995, 38, 3258-3263.	6.4	93
39	Histone acetyltransferase inhibitors and preclinical studies. Expert Opinion on Therapeutic Patents, 2009, 19, 761-774.	5.0	93
40	N $\langle \sup \rangle \hat{l}\mu \langle \sup \rangle$ -lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2795-2800.	7.1	93
41	Histone Deacetylase-3 Activation Promotes Tumor Necrosis Factor-α (TNF-α) Expression in Cardiomyocytes during Lipopolysaccharide Stimulation. Journal of Biological Chemistry, 2010, 285, 9429-9436.	3.4	89
42	Computer-Aided Design, Synthesis, and Anti-HIV-1 Activity in Vitro of 2-Alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)- ones as Novel Potent Non-Nucleoside Reverse Transcriptase Inhibitors, Also Active Against the Y181C Variant. Journal of Medicinal Chemistry, 2004, 47, 928-934.	6.4	85
43	Structure-Based Design, Synthesis, and Biological Evaluation of Conformationally Restricted Novel 2-Alkylthio-6-[1-(2,6-difluorophenyl)alkyl]- 3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase. Journal of Medicinal Chemistry, 2001, 44, 2544-2554.	6.4	84
44	Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1221-1225.	2.2	84
45	Discovery of Salermide-Related Sirtuin Inhibitors: Binding Mode Studies and Antiproliferative Effects in Cancer Cells Including Cancer Stem Cells. Journal of Medicinal Chemistry, 2012, 55, 10937-10947.	6.4	84
46	Sirtuin function in aging heart and vessels. Journal of Molecular and Cellular Cardiology, 2015, 83, 55-61.	1.9	83
47	p300/CBP-Associated Factor Selectively Regulates the Extinction of Conditioned Fear. Journal of Neuroscience, 2012, 32, 11930-11941.	3.6	82
48	Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structure–Activity Relationship, X-ray Crystal Structure, and Anticancer Activity. Journal of Medicinal Chemistry, 2017, 60, 2344-2360.	6.4	82
49	Crystal structures of the mitochondrial deacylase Sirtuin 4 reveal isoform-specific acyl recognition and regulation features. Nature Communications, 2017, 8, 1513.	12.8	80
50	3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a New Class of Synthetic Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2001, 44, 2069-2072.	6.4	79
51	The emerging role of lysine methyltransferase SETD8 in human diseases. Clinical Epigenetics, 2016, 8, 102.	4.1	77
52	Six Years (2012â€"2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2â€Pyridone Compounds. Chemical Record, 2018, 18, 1818-1832.	5.8	76
53	Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. Cell Death and Disease, 2018, 9, 996.	6.3	75
54	Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise. Current Pharmaceutical Design, 2009, 15, 3940-3957.	1.9	74

#	Article	IF	CITATIONS
55	Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. Aids, 2011, 25, 1347-1356.	2.2	74
56	A Nitric Oxide-dependent Cross-talk between Class I and III Histone Deacetylases Accelerates Skin Repair. Journal of Biological Chemistry, 2013, 288, 11004-11012.	3 . 4	74
57	Epigenetic polypharmacology: A new frontier for epiâ€drug discovery. Medicinal Research Reviews, 2020, 40, 190-244.	10.5	74
58	Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene, 2010, 29, 105-116.	5.9	73
59	The Innovative Potential of Statins in Cancer: New Targets for New Therapies. Frontiers in Chemistry, 2020, 8, 516.	3 . 6	73
60	3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs): A New Class of Specific Inhibitors of Human Immunodeficiency Virus Type 1. Antiviral Chemistry and Chemotherapy, 1993, 4, 361-368.	0.6	72
61	The emerging role of histone lysine demethylases in prostate cancer. Molecular Cancer, 2012, 11, 52.	19.2	72
62	Interplay among nucleosomal DNA, histone tails, and corepressor CoREST underlies LSD1-mediated H3 demethylation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2752-2757.	7.1	71
63	Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives. Journal of Medicinal Chemistry, 2017, 60, 4780-4804.	6.4	71
64	Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. Journal of Medicinal Chemistry, 2016, 59, 1501-1517.	6.4	70
65	The Histone Acetylase Activator Pentadecylidenemalonate 1b Rescues Proliferation and Differentiation in the Human Cardiac Mesenchymal Cells of Type 2 Diabetic Patients. Diabetes, 2014, 63, 2132-2147.	0.6	66
66	Binding Mode Analysis of 3-(4-Benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide:Â A New Synthetic Histone Deacetylase Inhibitor Inducing Histone Hyperacetylation, Growth Inhibition, and Terminal Cell Differentiation. Journal of Medicinal Chemistry, 2002, 45, 1778-1784.	6.4	65
67	3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through Structure-Based Drug Design and Docking Studiesâ€,Δ. Journal of Medicinal Chemistry, 2004, 47, 1351-1359.	6.4	65
68	Novel 3,5-Bis(bromohydroxybenzylidene)piperidin-4-ones as Coactivator-Associated Arginine Methyltransferase 1 Inhibitors: Enzyme Selectivity and Cellular Activity. Journal of Medicinal Chemistry, 2011, 54, 4928-4932.	6.4	65
69	Role of endogenous reverse transcriptase in murine early embryo development. Molecular Reproduction and Development, 2003, 66, 225-236.	2.0	64
70	Discovery of (Aryloxopropenyl)pyrrolyl Hydroxyamides as Selective Inhibitors of Class IIa Histone Deacetylase Homologue HD1-A. Journal of Medicinal Chemistry, 2003, 46, 4826-4829.	6.4	63
71	Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1132-1135.	2.2	63
72	Emerging approaches for histone deacetylase inhibitor drug discovery. Expert Opinion on Drug Discovery, 2015, 10, 599-613.	5.0	63

#	Article	IF	Citations
73	A closer look into NADPH oxidase inhibitors: Validation and insight into their mechanism of action. Redox Biology, 2020, 32, 101466.	9.0	62
74	3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C2and/or -C4Substitutions on Biological Activityâ€. Journal of Medicinal Chemistry, 2004, 47, 1098-1109.	6.4	61
75	The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene, 2014, 33, 4173-4184.	5.9	61
76	Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS. BMC Cancer, 2014, 14, 139.	2.6	61
77	Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features. Science Advances, 2016, 2, e1601017.	10.3	61
78	Sirtinol Treatment Reduces Inflammation in Human Dermal Microvascular Endothelial Cells. PLoS ONE, 2011, 6, e24307.	2.5	61
79	Design, Synthesis and Biological Evaluation of Carboxy Analogues of Arginine Methyltransferase Inhibitorâ€1 (AMIâ€1). ChemMedChem, 2010, 5, 398-414.	3.2	60
80	Protein Recognition by Short Peptide Reversible Inhibitors of the Chromatin-Modifying LSD1/CoREST Lysine Demethylase. ACS Chemical Biology, 2013, 8, 1677-1682.	3.4	60
81	1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. Journal of Medicinal Chemistry, 2016, 59, 1471-1491.	6.4	60
82	Synthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 6046-6056.	6.4	57
83	Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. Scientific Reports, 2017, 7, 44079.	3.3	57
84	Class II HDAC Inhibition Hampers Hepatic Stellate Cell Activation by Induction of MicroRNA-29. PLoS ONE, 2013, 8, e55786.	2.5	56
85	Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimerââ,¬â"¢s disease. Frontiers in Pharmacology, 2014, 5, 89.	3.5	56
86	Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid–induced differentiation. Science Advances, 2020, 6, eaax2746.	10.3	56
87	DNA Methyltransferases Inhibitors from Natural Sources. Current Topics in Medicinal Chemistry, 2015, 16, 680-696.	2.1	56
88	Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1537-1541.	2.2	55
89	Synthesis and Biological Properties of Novel 2-Aminopyrimidin-4(3H)-ones Highly Potent against HIV-1 Mutant Strains. Journal of Medicinal Chemistry, 2007, 50, 5412-5424.	6.4	55
90	Novel Histone Deacetylase Inhibitors Induce Growth Arrest, Apoptosis, and Differentiation in Sarcoma Cancer Stem Cells. Journal of Medicinal Chemistry, 2015, 58, 4073-4079.	6.4	55

#	Article	IF	Citations
91	Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells. Clinical Epigenetics, 2019, 11, 11.	4.1	55
92	The therapeutic uses of chromatin-modifying agents. Expert Opinion on Therapeutic Targets, 2007, 11, 835-851.	3.4	54
93	Combining 3-D Quantitative Structureâ^'Activity Relationship with Ligand Based and Structure Based Alignment Procedures for <i>in Silico</i> Screening of New Hepatitis C Virus NS5B Polymerase Inhibitors. Journal of Chemical Information and Modeling, 2010, 50, 662-676.	5.4	54
94	Evaluation of a large library of (thiazol-2-yl)hydrazones and analogues as histone acetyltransferase inhibitors: Enzyme and cellular studies. European Journal of Medicinal Chemistry, 2014, 80, 569-578.	5 . 5	54
95	Discovery of Inhibitors for the Ether Lipid-Generating Enzyme AGPS as Anti-Cancer Agents. ACS Chemical Biology, 2015, 10, 2589-2597.	3.4	54
96	HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. Journal of Molecular Endocrinology, 2010, 45, 219-228.	2.5	53
97	An Analog of BIX-01294 Selectively Inhibits a Family of Histone H3 Lysine 9 Jumonji Demethylases. Journal of Molecular Biology, 2012, 416, 319-327.	4.2	53
98	Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors. ChemMedChem, 2007, 2, 987-991.	3.2	52
99	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a Series of Anti-HIV-1 Agents of the Dihydro-alkoxy-benzyl-oxopyrimidine Family with Peculiar Structureâ^'Activity Relationship Profile. Journal of Medicinal Chemistry, 2008, 51, 4641-4652.	6.4	52
100	Chronic stress and antidepressant induced changes in Hdac5 and Sirt2 affect synaptic plasticity. European Neuropsychopharmacology, 2015, 25, 2036-2048.	0.7	51
101	Antimalarial and Antileishmanial Activities of Aroyl-Pyrrolyl-Hydroxyamides, a New Class of Histone Deacetylase Inhibitors. Antimicrobial Agents and Chemotherapy, 2004, 48, 1435-1436.	3.2	50
102	Nitric Oxide Determines Mesodermic Differentiation of Mouse Embryonic Stem Cells by Activating Class IIa Histone Deacetylases: Potential Therapeutic Implications in a Mouse Model of Hindlimb Ischemia. Stem Cells, 2010, 28, 431-442.	3.2	50
103	Discovery, Synthesis, and Pharmacological Evaluation of Spiropiperidine Hydroxamic Acid Based Derivatives as Structurally Novel Histone Deacetylase (HDAC) Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 3051-3064.	6.4	50
104	Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A. European Journal of Medicinal Chemistry, 2014, 86, 352-363.	5 . 5	50
105	New Insights on the Mechanism of Quinoline-based DNA Methyltransferase Inhibitors. Journal of Biological Chemistry, 2015, 290, 6293-6302.	3.4	50
106	Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression. Gastroenterology, 2021, 161, 1584-1600.	1.3	50
107	Synthesis and Antiviral Activity of New 3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs), Specific Inhibitors of Human Immunodeficiency Virus Type 1. Antiviral Chemistry and Chemotherapy, 1995, 6, 1-8.	0.6	49
108	Intergenerational inheritance of high fat diet-induced cardiac lipotoxicity in Drosophila. Nature Communications, 2019, 10, 193.	12.8	49

#	Article	IF	CITATIONS
109	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells. ACS Medicinal Chemistry Letters, 2020, 11, 977-983.	2.8	49
110	Sirt4: A Multifaceted Enzyme at the Crossroads of Mitochondrial Metabolism and Cancer. Frontiers in Oncology, 2020, 10, 474.	2.8	49
111	The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells. Oncotarget, 2017, 8, 68557-68570.	1.8	49
112	Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. Oncotarget, 2016, 7, 11332-11348.	1.8	49
113	HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 2030-2038.	4.1	48
114	Characterization of Sirtuin Inhibitors in Nematodes Expressing a Muscular Dystrophy Protein Reveals Muscle Cell and Behavioral Protection by Specific Sirtinol Analogues. Journal of Medicinal Chemistry, 2010, 53, 1407-1411.	6.4	48
115	A Novel Cell-Permeable, Selective, and Noncompetitive Inhibitor of KAT3 Histone Acetyltransferases from a Combined Molecular Pruning/Classical Isosterism Approach. Journal of Medicinal Chemistry, 2015, 58, 2779-2798.	6.4	48
116	Diarylpyrimidineâ^'Dihydrobenzyloxopyrimidine Hybrids: New, Wide-Spectrum Anti-HIV-1 Agents Active at (Sub)-Nanomolar Level. Journal of Medicinal Chemistry, 2011, 54, 3091-3096.	6.4	47
117	Targeting Lysine Deacetylases (KDACs) in Parasites. PLoS Neglected Tropical Diseases, 2015, 9, e0004026.	3.0	47
118	5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family. Bioorganic and Medicinal Chemistry, 2005, 13, 2065-2077.	3.0	46
119	Exploring the connection unit in the HDAC inhibitor pharmacophore model: Novel uracil-based hydroxamates. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4656-4661.	2.2	46
120	6-[1-(2,6-Difluorophenyl)ethyl]pyrimidinones Antagonize Cell Proliferation and Induce Cell Differentiation by Inhibiting (a Nontelomeric) Endogenous Reverse Transcriptase. Journal of Medicinal Chemistry, 2005, 48, 6776-6778.	6.4	46
121	A Photoreactive Small-Molecule Probe for 2-Oxoglutarate Oxygenases. Chemistry and Biology, 2011, 18, 642-654.	6.0	46
122	Sirtuin modulators: an updated patent review (2012 – 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 5-15.	5.0	46
123	LSD1 inhibitors: a patent review (2010-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 565-580.	5.0	46
124	The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases. Biochemical Pharmacology, 2016, 102, 130-140.	4.4	46
125	Histone deacetylase inhibitors may reduce pathogenicity and virulence in <i>Candida albicans</i> FEMS Yeast Research, 2007, 7, 1371-1380.	2.3	44
126	Non-Cancer Uses of Histone Deacetylase Inhibitors: Effects on Infectious Diseases and & Amp;#946;-Hemoglobinopathies+. Current Topics in Medicinal Chemistry, 2009, 9, 272-291.	2.1	44

#	Article	IF	CITATIONS
127	Identification of novel quinazoline derivatives as potent antiplasmodial agents. European Journal of Medicinal Chemistry, 2019, 161, 277-291.	5.5	44
128	The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice. Cardiovascular Research, 2010, 87, 73-82.	3.8	43
129	3-D QSAR Studies on Histone Deacetylase Inhibitors. A GOLPE/GRID Approach on Different Series of Compounds. Journal of Chemical Information and Modeling, 2006, 46, 1420-1430.	5.4	42
130	Novel benzofuran–chromone and –coumarin derivatives: synthesis and biological activity in K562 human leukemia cells. MedChemComm, 2013, 4, 1571.	3.4	41
131	Attenuation of diet-induced obesity and induction of white fat browning with a chemical inhibitor of histone deacetylases. International Journal of Obesity, 2017, 41, 289-298.	3.4	41
132	A NEW FACILE AND EXPEDITIOUS SYNTHESIS OF N-HYDROXY-N′-PHENYLOCTANEDIAMJDE, A POTENT INDUCE OF TERMINAL CYTODIFFERECNTIATION. Organic Preparations and Procedures International, 2001, 33, 391-394.	ER 1.3	40
133	ldentification of Tri―and Tetracyclic Pyrimidinediones as Sirtuin Inhibitors. ChemMedChem, 2010, 5, 674-677.	3.2	40
134	Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 $\hat{a} \in 2013$). Expert Opinion on Therapeutic Patents, 2014, 24, 401-415.	5.0	40
135	EZH2 inhibitors: a patent review (2014-2016). Expert Opinion on Therapeutic Patents, 2017, 27, 797-813.	5.0	40
136	RIP1–HAT1–SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer. Clinical Cancer Research, 2018, 24, 2886-2900.	7.0	40
137	Class II-selective histone deacetylase inhibitors. Part 2: Alignment-independent GRIND 3-D QSAR, homology and docking studies. European Journal of Medicinal Chemistry, 2008, 43, 621-632.	5.5	39
138	Histone deacetylase inhibitors: Keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacological Research, 2010, 62, 3-10.	7.1	39
139	Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2284-93.	7.1	39
140	Altered modulation of lamin A/Câ€HDAC2 interaction and <i>p21</i> expression during oxidative stress response in HGPS. Aging Cell, 2018, 17, e12824.	6.7	39
141	Sirtuin modulators: where are we now? A review of patents from 2015 to 2019. Expert Opinion on Therapeutic Patents, 2020, 30, 389-407.	5.0	39
142	Emerging Therapeutic Potential of SIRT6 Modulators. Journal of Medicinal Chemistry, 2021, 64, 9732-9758.	6.4	38
143	A novel Gcn5p inhibitor represses cell growth, gene transcription and histone acetylation in budding yeast. Biochemical Pharmacology, 2005, 70, 911-917.	4.4	37
144	Screen of Pseudopeptidic Inhibitors of Human Sirtuins 1â€"3: Two Lead Compounds with Antiproliferative Effects in Cancer Cells. Journal of Medicinal Chemistry, 2013, 56, 6681-6695.	6.4	36

#	Article	IF	Citations
145	3-(1H-Pyrrol-1-yl)-2-oxazolidinones as Reversible, Highly Potent, and Selective Inhibitors of Monoamine Oxidase Type A. Journal of Medicinal Chemistry, 2002, 45, 1180-1183.	6.4	35
146	Properly Substituted Analogues of BIX-01294 Lose Inhibition of G9a Histone Methyltransferase and Gain Selective Anti-DNA Methyltransferase 3A Activity. PLoS ONE, 2014, 9, e96941.	2.5	35
147	Novel inhibitors of human histone deacetylases: Design, synthesis and bioactivity of 3-alkenoylcoumarines. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3797-3801.	2.2	35
148	The Protein Arginine Methyltransferases 1 and 5 affect Myc properties in glioblastoma stem cells. Scientific Reports, 2019, 9, 15925.	3.3	35
149	Targeting histone acetylation/deacetylation in parasites: an update (2017–2020). Current Opinion in Chemical Biology, 2020, 57, 65-74.	6.1	35
150	Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Signaling in Breast Cancer. Cancers, 2019, 11, 2027.	3.7	34
151	Novel Reversible Monoamine Oxidase A Inhibitors: Highly Potent and Selective 3-(1 <i>Health of the Novel Reversible Monoamine Oxidase A Inhibitors: Highly Potent and Selective 3-(1<i>Health of the Novel Reversible Monoamine Oxidase A Inhibitors: Highly Potent and Selective 3-(1<i>Health of the Novel Reversible Monoamine Oxidase A Inhibitors: Highly Potent and Selective 3-(1<i) 3-(1<i)="" a="" and="" health="" hig<="" highly="" inhibitors:="" monoamine="" novel="" of="" oxidase="" potent="" reversible="" selective="" td="" the=""><td>6.4</td><td>33</td></i)></i></i></i>	6.4	33
152	Benzodeazaoxaflavins as Sirtuin Inhibitors with Antiproliferative Properties in Cancer Stem Cells. Journal of Medicinal Chemistry, 2012, 55, 8193-8197.	6.4	33
153	Context-Selective Death of Acute Myeloid Leukemia Cells Triggered by the Novel Hybrid Retinoid-HDAC Inhibitor MC2392. Cancer Research, 2014, 74, 2328-2339.	0.9	33
154	ll̂B Kinase Îμ Targets Interferon Regulatory Factor 1 in Activated T Lymphocytes. Molecular and Cellular Biology, 2014, 34, 1054-1065.	2.3	33
155	MC1568 inhibits HDAC6/8 activity and influenza A virus replication in lung epithelial cells: role of Hsp90 acetylation. Future Medicinal Chemistry, 2016, 8, 2017-2031.	2.3	33
156	A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. Molecular Cancer Therapeutics, 2018, 17, 1881-1892.	4.1	33
157	The Two-Faced Role of SIRT6 in Cancer. Cancers, 2021, 13, 1156.	3.7	33
158	Evaluation of Histone Deacetylases as Drug Targets in Huntington's Disease modelsStudy of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model PLOS Currents, 2010, 2, RRN1172.	1.4	33
159	Quinoline Derivative MC1626, a Putative GCN5 Histone Acetyltransferase (HAT) Inhibitor, Exhibits HAT-Independent Activity against Toxoplasma gondii. Antimicrobial Agents and Chemotherapy, 2007, 51, 1109-1111.	3.2	32
160	Synthesis and Biological Evaluation of N-Hydroxyphenylacrylamides and N-Hydroxypyridin-2-ylacrylamides as Novel Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 822-839.	6.4	32
161	Synthesis and structure–activity relationship of new cytotoxic agents targeting human glutathione-S-transferases. European Journal of Medicinal Chemistry, 2015, 89, 156-171.	5.5	32
162	Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity. Journal of Molecular Cell Biology, 2014, 6, 116-127.	3.3	31

#	Article	IF	CITATIONS
163	Enzyme kinetics and inhibition of histone acetyltransferase KAT8. European Journal of Medicinal Chemistry, 2015, 105, 289-296.	5.5	31
164	Analytical and semipreparative high performance liquid chromatography separation of stereoisomers of novel 3,4-dihydropyrimidin-4(3H)-one derivatives on the immobilised amylose-based Chiralpak IA chiral stationary phase. Journal of Separation Science, 2006, 29, 1399-1406.	2.5	30
165	Identification of Two New Synthetic Histone Deacetylase Inhibitors That Modulate Globin Gene Expression in Erythroid Cells from Healthy Donors and Patients with Thalassemia. Molecular Pharmacology, 2007, 72, 1111-1123.	2.3	30
166	Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment. Proteomics - Clinical Applications, 2010, 4, 71-83.	1.6	30
167	Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: Coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile. Bioorganic and Medicinal Chemistry, 2011, 19, 3659-3668.	3.0	30
168	Essential Oil Extraction, Chemical Analysis and Anti-Candida Activity of Calamintha nepeta (L.) Savi subsp. glandulosa (Req.) Ball—New Approaches. Molecules, 2017, 22, 203.	3.8	30
169	Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. Clinical Epigenetics, 2019, 11, 68.	4.1	30
170	Small-molecule chromatin-modifying agents: therapeutic applications. Epigenomics, 2010, 2, 307-324.	2.1	29
171	Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs). Bioorganic and Medicinal Chemistry, 2011, 19, 3690-3701.	3.0	29
172	P300/CBP Associated Factor Regulates Nitroglycerin-Dependent Arterial Relaxation by N ^ε -Lysine Acetylation of Contractile Proteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2435-2443.	2.4	29
173	2-(Alkyl/Aryl)Amino-6-Benzylpyrimidin-4($3 < i > H < l > $)-ones as Inhibitors of Wild-Type and Mutant HIV-1: Enantioselectivity Studies. Journal of Medicinal Chemistry, 2012, 55, 3558-3562.	6.4	29
174	Detrimental Effect of Class-selective Histone Deacetylase Inhibitors during Tissue Regeneration following Hindlimb Ischemia. Journal of Biological Chemistry, 2013, 288, 22915-22929.	3.4	29
175	Quinolineâ€Based p300 Histone Acetyltransferase Inhibitors with Proâ€apoptotic Activity in Human Leukemia U937 Cells. ChemMedChem, 2014, 9, 542-548.	3.2	29
176	A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Biochemical Pharmacology, 2015, 95, 16-27.	4.4	29
177	Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts. European Journal of Medicinal Chemistry, 2015, 94, 163-174.	5 . 5	28
178	Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells. Biochimie, 2012, 94, 2308-2313.	2.6	27
179	Chiral resolution and molecular modeling investigation ofrac-2-cyclopentylthio-6-[1-(2,6-difluorophenyl)ethyl]-3,4-dihydro-5-methylpyrimidin-4(3H)-one (MC-1047), a potent anti-HIV-1 reverse transcriptase agent of the DABO class. Chirality, 2001, 13, 75-80.	2.6	26
180	Structureâ€"Activity Relationship Studies on New DABOs: Effect of Substitutions at Pyrimidine C-5 and C-6 Positions on Anti-HIV-1 Activity. Antiviral Chemistry and Chemotherapy, 2001, 12, 37-50.	0.6	26

#	Article	IF	CITATIONS
181	Pharmacological inhibition of HDAC6 attenuates endothelial barrier dysfunction induced by thrombin. Biochemical and Biophysical Research Communications, 2011, 408, 630-634.	2.1	26
182	Histone Deacetylase Inhibitors: Structure-Based Modeling and Isoform-Selectivity Prediction. Journal of Chemical Information and Modeling, 2012, 52, 2215-2235.	5.4	26
183	Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogs of trichostatin A. Journal of Medicinal Chemistry, 1990, 33, 2845-2849.	6.4	25
184	Histone postâ€translational modifications by HPLCâ€ESIâ€MS after HT29 cell treatment with histone deacetylase inhibitors. Proteomics, 2009, 9, 5437-5445.	2.2	25
185	Polycomb Repressive Complex 2 Modulation through the Development of EZH2–EED Interaction Inhibitors and EED Binders. Journal of Medicinal Chemistry, 2021, 64, 11774-11797.	6.4	25
186	New pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme- and cell-based investigations. International Journal of Biochemistry and Cell Biology, 2009, 41, 235-247.	2.8	24
187	Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell proliferation and migration. Biochemical Pharmacology, 2014, 91, 181-190.	4.4	24
188	Pyrrole- and indole-containing tranylcypromine derivatives as novel lysine-specific demethylase 1 inhibitors active on cancer cells. MedChemComm, 2015, 6, 665-670.	3.4	24
189	Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells. European Journal of Medicinal Chemistry, 2017, 134, 316-333.	5.5	24
190	Lysine acetyltransferase inhibitors: structure–activity relationships and potential therapeutic implications. Future Medicinal Chemistry, 2018, 10, 1067-1091.	2.3	24
191	Sirtuin modulators: past, present, and future perspectives. Future Medicinal Chemistry, 2022, 14, 915-939.	2.3	24
192	Synthesis and Biological Evaluation of 2-, 3-, and 4-Acylaminocinnamyl-Nhydroxyamides as Novel Synthetic HDAC Inhibitors. Medicinal Chemistry, 2005, 1, 245-254.	1.5	23
193	Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLF and pERK present in human erythroid cells. International Journal of Biochemistry and Cell Biology, 2014, 50, 112-122.	2.8	23
194	HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal. Scientific Reports, 2018, 8, 8492.	3.3	23
195	Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. Current Opinion in Chemical Biology, 2019, 50, 89-100.	6.1	23
196	Statins and Histone Deacetylase Inhibitors Affect Lamin A/C – Histone Deacetylase 2 Interaction in Human Cells. Frontiers in Cell and Developmental Biology, 2019, 7, 6.	3.7	23
197	Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1651-1656.	2.2	22
198	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: Histone deacetylase inhibition and in-cell activities. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2530-2535.	2.2	22

#	Article	IF	CITATIONS
199	Identification of Small-Molecule Enhancers of Arginine Methylation Catalyzed by Coactivator-Associated Arginine Methyltransferase 1. Journal of Medicinal Chemistry, 2012, 55, 9875-9890.	6.4	22
200	Effect of Class II HDAC inhibition on glutamate transporter expression and survival in SOD1-ALS mice. Neuroscience Letters, 2017, 656, 120-125.	2.1	22
201	Effects of Class II-Selective Histone Deacetylase Inhibitor on Neuromuscular Function and Disease Progression in SOD1-ALS Mice. Neuroscience, 2018, 379, 228-238.	2.3	22
202	H19-Dependent Transcriptional Regulation of \hat{l}^2 3 and \hat{l}^2 4 Integrins Upon Estrogen and Hypoxia Favors Metastatic Potential in Prostate Cancer. International Journal of Molecular Sciences, 2019, 20, 4012.	4.1	22
203	Lysine Acetyltransferase Inhibitors From Natural Sources. Frontiers in Pharmacology, 2020, 11, 1243.	3.5	22
204	A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts. Oncotarget, 2015, 6, 4126-4143.	1.8	22
205	Identification of Structural Features of 2â€Alkylideneâ€1,3â€Dicarbonyl Derivatives that Induce Inhibition and/or Activation of Histone Acetyltransferases KAT3B/p300 and KAT2B/PCAF. ChemMedChem, 2015, 10, 144-157.	3.2	21
206	Acute and chronic neurobehavioral effects of the designer drug and bath salt constituent 3,4-methylenedioxypyrovalerone in the rat. Journal of Psychopharmacology, 2019, 33, 392-405.	4.0	21
207	Therapeutic Potential and Activity Modulation of the Protein Lysine Deacylase Sirtuin 5. Journal of Medicinal Chemistry, 2022, 65, 9580-9606.	6.4	21
208	N-[4-(1,1′-biphenyl)methyl]-4-(4-thiomorpholinylmethyl) benzenamines as non-oxazolidinone analogues of antimycobacterial U-100480. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 1493-1498.	2.2	20
209	Synthesis and biological evaluation of enantiomerically pure pyrrolyl-oxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors. Il Farmaco, 2003, 58, 231-241.	0.9	20
210	Aroyl-Pyrrolyl Hydroxyamides: Influence of Pyrrole C4-Phenylacetyl Substitution on Histone Deacetylase Inhibition. ChemMedChem, 2006, 1, 225-237.	3.2	20
211	Histone deacetylase inhibitors restore IL-10 expression in lipopolysaccharide-induced cell inflammation and reduce IL- $\hat{\Pi}^2$ and IL-6 production in breast silicone implant in C57BL/6J wild-type murine model. Autoimmunity, 2016, 49, 155-165.	2.6	20
212	Histone Deacetylases Contribute to Excitotoxicity-Triggered Degeneration of Retinal Ganglion Cells In Vivo. Molecular Neurobiology, 2019, 56, 8018-8034.	4.0	20
213	CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas. Frontiers in Pharmacology, 2020, 11, 1230.	3.5	20
214	New 6-nitroquinolones: synthesis and antimicrobial activities. Il Farmaco, 2004, 59, 463-471.	0.9	19
215	Slow-, Tight-Binding HIV-1 Reverse Transcriptase Non-Nucleoside Inhibitors Highly Active against Drug-Resistant Mutants. ChemMedChem, 2007, 2, 445-448.	3.2	19
216	Application of $3\hat{1}\frac{1}{4}$ m particle-based amylose-derived chiral stationary phases for the enantioseparation of potential histone deacetylase inhibitors. Journal of Chromatography A, 2011, 1218, 8394-8398.	3.7	19

#	Article	IF	CITATIONS
217	Syntheses of 3b,4,6,7-Tetrahydro-5h,9h-pyrazino [2,1-c] phyrolo[1,2-a] [1,4] benzodiazepine, a valuable precursor of potential central nervous system agents. Tetrahedron, 1989, 45, 2763-2772.	1.9	18
218	Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors. ChemMedChem, 2016, 11, 1680-1685.	3.2	18
219	Structureâ€"Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from <i>Schistosoma mansoni</i> (<i>Sm</i> Sirt2). Journal of Medicinal Chemistry, 2019, 62, 8733-8759.	6.4	18
220	\hat{l}_{\pm},\hat{l}^3 -Diketocarboxylic Acids and Their Esters Act as Carbonic Anhydrase IX and XII Selective Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 661-665.	2.8	18
221	Tranylcypromineâ€Based LSD1 Inhibitors: Structureâ€Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation. ChemMedChem, 2020, 15, 643-658.	3.2	18
222	Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells. American Journal of Cancer Research, 2016, 6, 859-75.	1.4	18
223	Novel Cinnamyl Hydroxyamides and 2â€Aminoanilides as Histone Deacetylase Inhibitors: Apoptotic Induction and Cytodifferentiation Activity. ChemMedChem, 2011, 6, 698-712.	3.2	17
224	Screening Assays for Epigenetic Targets Using Native Histones as Substrates. Journal of Biomolecular Screening, 2012, 17, 18-26.	2.6	17
225	Exploring the Role of 2-Chloro-6-fluoro Substitution in 2-Alkylthio-6-benzyl-5-alkylpyrimidin-4(3 <i>HReverse Transcriptase Enzymes. Journal of Medicinal Chemistry, 2014, 57, 5212-5225.</i>	6.4	17
226	A new nitrobenzoxadiazole-based GSTP1-1 inhibitor with a previously unheard of mechanism of action and high stability. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 240-247.	5.2	17
227	Metabolite profiling of ascidian Styela plicata using LC–MS with multivariate statistical analysis and their antitumor activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 614-623.	5.2	17
228	Synthesis of a new tetracyclic system related to aptazapine (CGS 7525A) by one-pot double annelation. Tetrahedron Letters, 1988, 29, 6471-6474.	1.4	16
229	Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives. Journal of Medicinal Chemistry, 1992, 35, 4533-4541.	6.4	16
230	<i>tert</i> â€Butylcarbamateâ€Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells. ChemMedChem, 2013, 8, 800-811.	3.2	16
231	Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies. ACS Medicinal Chemistry Letters, 2015, 6, 173-177.	2.8	16
232	Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer. International Journal of Molecular Sciences, 2019, 20, 5654.	4.1	16
233	Altered mitochondrial function in cells carrying a premutation or unmethylated full mutation of the FMR1 gene. Human Genetics, 2020, 139, 227-245.	3.8	16
234	SIRT5 Inhibition Induces Brown Fat-Like Phenotype in 3T3-L1 Preadipocytes. Cells, 2021, 10, 1126.	4.1	16

#	Article	IF	CITATIONS
235	Lysine Acetylation Regulates Bruton's Tyrosine Kinase in B Cell Activation. Journal of Immunology, 2010, 184, 244-254.	0.8	15
236	Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches. Journal of Computer-Aided Molecular Design, 2018, 32, 435-458.	2.9	15
237	Development of alkyl glycerone phosphate synthase inhibitors: Structure-activity relationship and effects on ether lipids and epithelial-mesenchymal transition in cancer cells. European Journal of Medicinal Chemistry, 2019, 163, 722-735.	5 . 5	15
238	Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. European Journal of Medicinal Chemistry, 2022, 237, 114410.	5 . 5	15
239	Histone deacetylase inhibitors and hemoglobin F induction in \hat{I}^2 -thalassemia. International Journal of Biochemistry and Cell Biology, 2008, 40, 2341-2347.	2.8	14
240	Revelations into resveratrol's mechanism. Nature Medicine, 2012, 18, 500-501.	30.7	14
241	Carprofen Analogues as Sirtuin Inhibitors: Enzyme and Cellular Studies. ChemMedChem, 2012, 7, 1905-1908.	3.2	14
242	EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers. Frontiers in Pediatrics, 2018, 6, 328.	1.9	14
243	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 <i>H</i>)-ones. Journal of Medicinal Chemistry, 2019, 62, 604-621.	6.4	14
244	Histoneâ€deacetylase 8 drives the immune response and the growth of glioma. Glia, 2021, 69, 2682-2698.	4.9	14
245	Oneâ€pot synthesis of novel spiroâ€annelated pyrroleâ€containing heterocyclic systems from suitable synthons. Journal of Heterocyclic Chemistry, 1992, 29, 241-245.	2.6	13
246	Pyrrolobenzodiazepines with antinociceptive activity: synthesis and pharmacological activities. European Journal of Medicinal Chemistry, 1995, 30, 593-601.	5 . 5	13
247	Investigation on QSAR and binding mode of a new class of human rhinovirus-14 inhibitors by CoMFA and docking experiments. Bioorganic and Medicinal Chemistry, 1996, 4, 1715-1724.	3.0	13
248	Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. International Journal of Biochemistry and Cell Biology, 2007, 39, 1510-1522.	2.8	13
249	Synthesis and Biological Characterization of Amidopropenyl Hydroxamates as HDAC Inhibitors. ChemMedChem, 2010, 5, 1359-1372.	3.2	13
250	Modulation of Cell Differentiation, Proliferation, and Tumor Growth by Dihydrobenzyloxopyrimidine Non-Nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 5927-5936.	6.4	13
251	Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170150.	4.0	13
252	Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. Oncotarget, 2018, 9, 25647-25660.	1.8	13

#	Article	IF	CITATIONS
253	Effects of Structurally Different HDAC Inhibitors against <i>Trypanosoma cruzi</i> , <i>Leishmania</i> , and <i>Schistosoma mansoni</i> . ACS Infectious Diseases, 2022, 8, 1356-1366.	3.8	13
254	Researches on Antibacterial and Antifungal Agents, X. Synthesis and Antifungal Activities of 1-{p-Methyl-α-[4-(1H-pyrrol-1-yl)phenyl]benzyl}azoles and Some Related Products. Archiv Der Pharmazie, 1989, 322, 369-373.	4.1	12
255	6-Alkylthio-4-[1-(2,6-difluorophenyl)alkyl]-1H-[1,3,5]triazin-2-ones (ADATs): Novel Regulators of Cell Differentiation and Proliferation. ChemMedChem, 2006, 1, 1073-1080.	3.2	12
256	Chiral HPLC separation and absolute configuration of novel <i>S</i> â€DABO derivatives. Chirality, 2009, 21, 604-612.	2.6	12
257	Biological Effects of MC2050, a Quinazolineâ∈Based PARPâ∈1 Inhibitor, in Human Neuroblastoma and EBVâ∈Positive Burkittâ∈2s Lymphoma Cells. ChemMedChem, 2011, 6, 606-611.	3.2	12
258	Reactivity of 4â€Vinylâ€2 <i>H</i> â€1â€benzopyranâ€2â€ones in Diels–Alder Cycloaddition Reactions: Access t Coumarinâ€Based Polycycles with Cdc25 Phosphataseâ€Inhibiting Activity. European Journal of Organic Chemistry, 2013, 2013, 2869-2877.	2.4	12
259	Targeting Epigenetics in Drug Discovery. ChemMedChem, 2014, 9, 415-417.	3.2	12
260	KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2. Clinical Epigenetics, 2018, 10, 44.	4.1	12
261	Application of Small Epigenetic Modulators in Pediatric Medulloblastoma. Frontiers in Pediatrics, 2018, 6, 370.	1.9	12
262	Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs). European Journal of Medicinal Chemistry, 2020, 207, 112750.	5 . 5	12
263	Epigenetic Metalloenzymes. Current Medicinal Chemistry, 2019, 26, 2748-2785.	2.4	12
264	A potent HDAC inhibitor blocks Toxoplasma gondii tachyzoite growth and profoundly disrupts parasite gene expression. International Journal of Antimicrobial Agents, 2022, 59, 106526.	2.5	12
265	Transcriptomic and genomic studies classify NKL54 as a histone deacetylase inhibitor with indirect influence on MEF2-dependent transcription. Nucleic Acids Research, 2022, 50, 2566-2586.	14.5	12
266	Targeting the anti-apoptotic Bcl-2 family proteins: machine learning virtual screening and biological evaluation of new small molecules. Theranostics, 2022, 12, 2427-2444.	10.0	12
267	Chemogenomic profiling of the cellular effects associated with histone H3 acetylation impairment by a quinoline-derived compound. Genomics, 2010, 96, 272-280.	2.9	11
268	6-(Arylmethyl)pyrimidin-4(3H)-ones: anthology and prospects of highly efficient anti-HIV agents. Russian Chemical Bulletin, 2012, 61, 1399-1418.	1.5	11
269	Structure–Activity Relationships on Cinnamoyl Derivatives as Inhibitors of p300 Histone Acetyltransferase. ChemMedChem, 2017, 12, 1359-1368.	3.2	11
270	Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity. Bioorganic and Medicinal Chemistry, 2017, 25, 847-856.	3.0	11

#	Article	IF	CITATIONS
271	Nucleocytoplasmic export of HDAC5 and SIRT2 downregulation: two epigenetic mechanisms by which antidepressants enhance synaptic plasticity markers. Psychopharmacology, 2018, 235, 2831-2846.	3.1	11
272	Inhibition of class I HDACs imprints adipogenesis toward oxidative and brown-like phenotype. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158594.	2.4	11
273	Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) induces global transcriptional deregulation and ultrastructural alterations that impair viability in Schistosoma mansoni. PLoS Neglected Tropical Diseases, 2020, 14, e0008332.	3.0	11
274	Histone Modifications, Stem Cells and Prostate Cancer. Current Pharmaceutical Design, 2014, 20, 1687-1697.	1.9	11
275	Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1339-1359.	7.3	11
276	Biochemical Functions and Clinical Characterizations of the Sirtuins in Diabetes-Induced Retinal Pathologies. International Journal of Molecular Sciences, 2022, 23, 4048.	4.1	11
277	Heterocyclic system. XI . Synthesis of 1 <i>H</i> ,4 <i>H</i> êpyrazolo[4,3â€ <i>b</i>]pyrrolizine and 2 <i>H</i> ,4 <i>H</i> ,100,000 ft. Beterocyclic Chemistry, 1990, 27, 1805-1808.	2.6	10
278	Spiro-[4 <i>H</i> -pyrrolo[1,2-a][1,4]benzodiazepine-4,4′-piperidine] Derivatives as Potential Nootropic Agents: A Simple One-Pot Synthesis. Synthetic Communications, 1990, 20, 3537-3545.	2.1	10
279	Trends of LSD1 inhibitors in viral infections. Future Medicinal Chemistry, 2018, 10, 1133-1136.	2.3	10
280	Regulatory Interplay between miR-181a-5p and Estrogen Receptor Signaling Cascade in Breast Cancer. Cancers, 2021, 13, 543.	3.7	10
281	Pyrroleâ€Based Hydroxamates and 2â€Aminoanilides: Histone Deacetylase Inhibition and Cellular Activities. ChemMedChem, 2009, 4, 1411-1415.	3.2	9
282	Epigenetic modulation of PGC-1 \hat{l} ± activity by GCN5 inhibitors: WO2010007085. Expert Opinion on Therapeutic Patents, 2011, 21, 1651-1656.	5.0	9
283	PRMT1 arginine methyltransferase accumulates in cytoplasmic bodies that respond to selective inhibition and DNA damage. European Journal of Histochemistry, 2014, 58, 2389.	1.5	9
284	Amphetamine and the Smart Drug 3,4-Methylenedioxypyrovalerone (MDPV) Induce Generalization of Fear Memory in Rats. Frontiers in Molecular Neuroscience, 2019, 12, 292.	2.9	9
285	5,6-Dihydro-4H-pyrrolo[1,2-a][1,4]benzodiazepine-4,4-diacetic acid diethyl ester, an useful synthon for the synthesis of new polycyclic nitrogen systems of pharmacological interest. Journal of Heterocyclic Chemistry, 1993, 30, 897-903.	2.6	8
286	Substrate-Induced Stable Enzyme-Inhibitor Complex Formation Allows Tight Binding of Novel 2-Aminopyrimidin-4(3H)-ones to Drug-Resistant HIV-1 Reverse Transcriptase Mutants. ChemMedChem, 2008, 3, 1412-1418.	3.2	8
287	Identification of Smallâ€Molecule Inhibitors of the XendoU Endoribonucleases Family. ChemMedChem, 2011, 6, 1797-1805.	3.2	8
288	From PARP1 to TNKS2 Inhibition: A Structure-Based Approach. ACS Medicinal Chemistry Letters, 2020, 11, 862-868.	2.8	8

#	Article	IF	Citations
289	Identification of Inhibitors to Trypanosoma cruzi Sirtuins Based on Compounds Developed to Human Enzymes. International Journal of Molecular Sciences, 2020, 21, 3659.	4.1	8
290	The Pan-Sirtuin Inhibitor MC2494 Regulates Mitochondrial Function in a Leukemia Cell Line. Frontiers in Oncology, 2020, 10, 820.	2.8	8
291	Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. Cancers, 2020, 12, 447.	3.7	8
292	Downregulation of miRâ€326 and its host gene βâ€arrestin1 induces proâ€survival activity of E2F1 and promotes medulloblastoma growth. Molecular Oncology, 2021, 15, 523-542.	4.6	8
293	Novel Pyridineâ€Based Hydroxamates and 2′â€Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. ChemMedChem, 2021, 16, 989-999.	3.2	8
294	Histone deacetylase inhibition modulates deoxyribonucleotide pools and enhances the antitumor effects of the ribonucleotide reductase inhibitor 3'-C-methyladenosine in leukaemia cells. International Journal of Oncology, 2011, 38, 1427-36.	3.3	7
295	Developing novel non-hydroxamate histone deacetylaseinhibitors: the chelidamic warhead. MedChemComm, 2012, 3, 298-304.	3.4	7
296	Chemical epigenetics to assess the role of HDAC1–3 inhibition in macrophage pro-inflammatory gene expression. MedChemComm, 2016, 7, 2184-2190.	3.4	7
297	The relevance of K i calculation for bi-substrate enzymes illustrated by kinetic evaluation of a novel lysine (K) acetyltransferase 8 inhibitor. European Journal of Medicinal Chemistry, 2017, 136, 480-486.	5.5	7
298	First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53. Journal of Medicinal Chemistry, 2021, 64, 17031-17050.	6.4	7
299	Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibroâ€adipogenic progenitors. EMBO Reports, 2022, 23, e54721.	4.5	7
300	Antifungal Agents, II: Synthesis and Antifungal Activities of Aryl-1H-pyrrol-2-yl-1H-imidazol-1-yl-methane Derivatives with Unsaturated Chains. Archiv Der Pharmazie, 1993, 326, 539-546.	4.1	6
301	[[[(Thienylcarbonyl)alkyl]oxy]phenyl]- and [[[(Pyrrylcarbonyl)alkyl]oxy]phenyl]oxazoline Derivatives with Potent and Selective Antihuman Rhinovirus Activity. Journal of Medicinal Chemistry, 1995, 38, 803-809.	6.4	6
302	Mass spectrometry enables the discovery of inhibitors of an LPS transport assembly <i>via</i> disruption of proteinâ€"protein interactions. Chemical Communications, 2021, 57, 10747-10750.	4.1	6
303	Synthesis of new disoxaril analogues with potent and selective anti-human rhinovirus 14 activity. Bioorganic and Medicinal Chemistry Letters, 1991, 1, 575-578.	2.2	5
304	Synthesis of pyrazole analogues of isoaptazepine. Journal of Heterocyclic Chemistry, 1992, 29, 1851-1854.	2.6	5
305	Photoactivable peptides for identifying enzyme–substrate and protein–protein interactions. Chemical Communications, 2011, 47, 1488-1490.	4.1	5
306	Detrimental effects of the †bath salt†methylenedioxypyrovalerone on social play behavior in male rats. Neuropsychopharmacology, 2020, 45, 2012-2019.	5.4	5

#	Article	IF	CITATIONS
307	Anti-influenza A virus activity and structure–activity relationship of a series of nitrobenzoxadiazole derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 2128-2138.	5.2	5
308	Combined HAT/EZH2 modulation leads to cancer-selective cell death. Oncotarget, 2018, 9, 25630-25646.	1.8	5
309	Synthesis and biochemical evaluation of (R)-5-acyloxymethyl- and (S)-5-acylaminomethyl-3-(1H-pyrrol-1-yl)-2-oxazolidinones as new anti-monoamine oxidase (anti-MAO) agents. Arkivoc, 2004, 2004, 32-43.	0.5	5
310	Identification of small molecules inhibitors of GCN5 histone acetyltransferase activity. Arkivoc, 2006, 2006, 24-37.	0.5	5
311	Methyl-2-Thienylketopolymethyleneoxyphenyl Derivatives of Alkyl-Substituted 4,5-Dihydro-Oxazoles with Anti-Human Picornavirus Activity. Antiviral Chemistry and Chemotherapy, 1996, 7, 213-220.	0.6	4
312	Reactions of 6-benzyl-5-methyl-2-(methylsulfanyl)pyrimidin-4(3H)-one with aliphatic and aliphatic-aromatic amines. Russian Journal of Organic Chemistry, 2009, 45, 773-776.	0.8	4
313	Structural Basis of Sirtuin 6 Activation by Synthetic Small Molecules. Angewandte Chemie, 2017, 129, 1027-1031.	2.0	4
314	Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells. Molecules, 2020, 25, 3122.	3.8	4
315	Diphenylene Iodonium Is a Noncovalent MAO Inhibitor: A Biochemical and Structural Analysis. ChemMedChem, 2020, 15, 1394-1397.	3.2	4
316	Discovery of the First Human Arylsulfatase A Reversible Inhibitor Impairing Mouse Oocyte Fertilization. ACS Chemical Biology, 2020, 15, 1349-1357.	3.4	4
317	Novel Targeting of DNA Methyltransferase Activity Inhibits Ewing Sarcoma Cell Proliferation and Enhances Tumor Cell Sensitivity to DNA Damaging Drugs by Activating the DNA Damage Response. Frontiers in Endocrinology, 2022, 13, .	3.5	4
318	Arylketotetramethylene Analogues of Disoxaril with Anti-Human Rhinovirus 14 Activity. Antiviral Chemistry and Chemotherapy, 1997, 8, 235-242.	0.6	3
319	Comparison of the effects of synthetic and plant-derived mTOR regulators on healthy human ovarian cells. European Journal of Pharmacology, 2019, 854, 70-78.	3.5	3
320	The Nitrobenzoxadiazole Derivative NBDHEX Behaves as Plasmodium falciparum Gametocyte Selective Inhibitor with Malaria Parasite Transmission Blocking Activity. Pharmaceuticals, 2022, 15, 168.	3.8	3
321	Pyrrylphenylethanones Related to Cathinone and Lefetamine: Synthesis and Pharmacological Activities. Archiv Der Pharmazie, 1992, 325, 403-409.	4.1	2
322	Oneâ€Pot, Highâ€Yielding Synthesis of Novel Dihydrothiazolo[3,2â€a]pyrimidinones. Synthetic Communications, 2006, 36, 495-500.	2.1	2
323	Correction for Colussi et al., HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1679-1679.	7.1	2
324	HAT inhibitors in cancer therapy. , 2020, , 51-80.		2

#	Article	IF	CITATIONS
325	Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 973-985.	5.2	2
326	Sex-dependent Effects of the Drugs of Abuse Amphetamine and the Smart Drug 3,4-Methylenedioxypyrovalerone on Fear Memory Generalization in Rats. Neuroscience, 2021, , .	2.3	2
327	Stereoselective synthesis of 2-substituted 6-[1-(2,6-difluorophenyl)ethyl]-5-methylpyrimidin-4(3H)-ones. Russian Journal of Organic Chemistry, 2009, 45, 1531-1534.	0.8	1
328	The specific character of the reaction of derivatives of 2-thioxo-2,3-dihydropyrimidin-4(1H)-one with iodomethane and alkyl chloromethyl sulfides. Chemistry of Heterocyclic Compounds, 2010, 46, 200-205.	1,2	1
329	Amphetamine Modulation of Long-Term Object Recognition Memory in Rats: Influence of Stress. Frontiers in Pharmacology, 2021, 12, 644521.	3.5	1
330	Identification of specific and semi-specific SIRT inhibitors through computer-aided studies. Aging, 2011, 3, 819-820.	3.1	1
331	Histone Deacetylase inhibitors modulate mitochondrial biogenesis in skeletal muscle. FASEB Journal, 2010, 24, lb119.	0.5	1
332	DNA Methylation: Biological Implications and Modulation of Its Aberrant Dysregulation. RNA Technologies, 2019, , 295-331.	0.3	1
333	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDACâ€MEF2 complexes. EMBO Reports, 2020, 21, e51028.	4.5	1
334	Inhibition of PKCÎ, Improves Dystrophic Heart Phenotype and Function in a Novel Model of DMD Cardiomyopathy. International Journal of Molecular Sciences, 2022, 23, 2256.	4.1	1
335	Synthesis and in vitro Antimycobacterial Activity of Novel 3-(1H-Pyrrol-1-yl)-2-oxazolidinone Analogues of PNU-100480 ChemInform, 2004, 35, no.	0.0	0
336	New 6-Nitroquinolones: Synthesis and Antimicrobial Activities ChemInform, 2004, 35, no.	0.0	0
337	Histone Deacetylation in Epigenetics: An Attractive Target for Anticancer Therapy. ChemInform, 2005, 36, no.	0.0	0
338	CS03-5. IRF-1 phosphorylation by I-kappa-B kinase epsilon impairs IFN beta stimulation in activated CD4+ T cells Cytokine, 2011, 56, 9.	3.2	0
339	Epigenetic drugs targeting cccDNA-bound chromatin modifying enzymes silence HBV transcription and inhibit viral replication. Digestive and Liver Disease, 2014, 46, e25.	0.9	0
340	Epigenetic Pharmacology in Regenerative Medicine (Epi-Drugs)., 2019,, 405-444.		0
341	Sirtuins., 2021, , 1-15.		0
342	Aroyl-Pyrrolyl-Hydroxy-Amides (APHAs), a Novel Family of Synthetic Histone Deacetylases Inhibitors, Are Potent Inducers of Human g-Globin Gene Expression Blood, 2004, 104, 1216-1216.	1.4	0

#	Article	IF	CITATIONS
343	Ontogenic-Specific Increasesin HDAC1 Activity and Transcription Factor Association During the Maturation of Human Adult Erythroblasts in Vitro Blood, 2009, 114, 1978-1978.	1.4	O
344	The effect of mTOR blockers on japanese quail ovarian granulosa cell functions. Endocrine Abstracts, 0 , , 1 - 1 .	0.0	0
345	Abstract 2946: Effects of two novel quinoline-based non-nucleoside DNA methyltransferase inhibitors against bone sarcomas. , 2015, , .		0
346	Medicinal Chemistry â \in " Research and Publishing. ChemistryViews, 0, , .	0.0	0
347	Sirtuins., 2021, , 1422-1435.		0
348	Title is missing!. , 2020, 14, e0008332.		0
349	Title is missing!. , 2020, 14, e0008332.		0
350	Title is missing!. , 2020, 14, e0008332.		0
351	Title is missing!. , 2020, 14, e0008332.		O